City State Bank’s Fortress Biotech FBIO Stock Holding History

City State Bank’s Portfolio FBIO Stock Details FBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-8	Closed	–	–	669
2022 Q3	$0	Hold	8	–	–	﹤0.01%	671
2022 Q2	$0	Buy	+8	New	+$119	﹤0.01%	675

Other funds holding FBIO

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OMC

Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Corient Private Wealth Miami, Florida $69.9B AUM 22.19% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

City State Bank's FBIO Position: Q4 2022 in Review

City State Bank sold out of Fortress Biotech (FBIO) in Q4 2022, closing a stake of 8 shares.

City State Bank first reported a position in FBIO in Q2 2022 and held it in 2 quarters. The position peaked at $0 in Q3 2022. 49 funds tracked by Wall St. Rank hold FBIO as of Q4 2022.

City State Bank reported no remaining Fortress Biotech position as of Q4 2022 after selling out during the quarter.
City State Bank sold 8 Fortress Biotech shares in Q4 2022.
City State Bank first reported a position in Fortress Biotech in Q2 2022 and held it in 2 quarters.
City State Bank's Fortress Biotech position peaked at $0 in Q3 2022.
49 funds tracked by Wall St. Rank held Fortress Biotech as of Q4 2022.

Based on City State Bank's 13F filing for Q4 2022, filed 12 Jan 2023.